Dow Tumbles Over 300 Points, Market Volatility Rises Sharply

US stocks closed sharply lower on Thursday as investors digested the recent economic reports. US jobless claims increased by 2,000 to 216,000 in the week ending December 17, compared to market estimates of 220,000. The US economy, meanwhile, expanded an annualized 3.2% on quarter in the third quarter, up from 2.9% in the second estimate.

US stocks closed sharply lower on Thursday as investors digested the recent economic reports.

US jobless claims increased by 2,000 to 216,000 in the week ending December 17, compared to market estimates of 220,000. The US economy, meanwhile, expanded an annualized 3.2% on quarter in the third quarter, up from 2.9% in the second estimate.

Investors remained concerned that major central banks around the world will continue tightening their monetary policies.

All the major sectors on the S&P 500 closed on a negative note, with information technology and consumer discretionary stocks recording the biggest plunge on Thursday.

The Nasdaq 100 dipped 2.49% to close at 10,956.14 on Thursday, amid decline in shares of Amazon.com, Inc. (NASDAQ:AMZN) and Tesla Inc (NASDAQ:TSLA). The S&P 500 fell 1.45%, while the Dow Jones dropped 1.05% to 33,027.49 in the previous session.

The Chicago Board Options Exchange’s CBOE Volatility Index (VIX) jumped 9.5% to 21.97 points on Thursday.

What is CBOE Volatility Index?

The CBOE Volatility Index, popularly known as VIX, is a measure of the equity market’s expectation of volatility based on S&P 500 index call and put options.

Read Next: Mitsubishi UFJ Financial, Sumitomo Mitsui Financial And These Most Expensive Majors In The Financial Sector

Total
0
Shares
Related Posts
Read More

Nanobiotix Announces Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 In Locally Advanced Head And Neck Cancer Showing Median Progression-Free Survival Of 16.9 Months And Median Overall Survival Of 23.1 Months

Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently high injected-lesion overall

NBTX